The Proposed Design to Fix Ceiling Prices Under 2013 DPCO

Ajay Bhaskarabhatla
Additional contact information
Ajay Bhaskarabhatla: Erasmus University Rotterdam

Chapter Chapter 4 in Regulating Pharmaceutical Prices in India, 2018, pp 71-80 from Springer

Abstract: Abstract In previous chapters, we presented a brief overview of the history of pharmaceutical price regulation in India over a period of 4 decades and a case to motivate the need for regulating pharmaceutical prices in India in 2013. In this chapter, we examine the details of the 2013 DPCO design before we assess its success in limiting pharmaceutical prices. We begin by recalling the key differences between the 1995 and 2013 DPCO and describing the manner in which the ceiling price is estimated by the NPPA. The chapter not only anticipates the potential problems associated with the implementation of the design but also highlights how pharmaceutical firms can circumvent price controls.

Keywords: Price Ceiling; National Pharmaceutical Pricing Authority (NPPA); National List Of Essential Medicines (NLEM); Stock Keeping Units (SKU); Market-based Data (search for similar items in EconPapers)
Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:isbchp:978-3-319-93393-1_4

Ordering information: This item can be ordered from
http://www.springer.com/9783319933931

DOI: 10.1007/978-3-319-93393-1_4

Access Statistics for this chapter

More chapters in India Studies in Business and Economics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().